In section Market Quotes

J&J Seeks FDA Approval for Caplyta in Bipolar I Mania

Johnson & Johnson has asked U.S. regulators to expand Caplyta’s approved uses to include manic or mixed episodes associated with bipolar I disorder in adults. The filing follows a late-stage study result the company reported last week and could give the drug its fifth approved use in adults.

J&J Seeks FDA Approval for Caplyta in Bipolar I Mania

The New Brunswick, N.J.-based company said its application is for treating adults with manic or mixed episodes linked to bipolar I disorder. J&J said approval would make this the fifth adult use cleared for Caplyta.

The antipsychotic is already approved for depressive episodes associated with bipolar I or II disorder, schizophrenia and major depressive disorder. Last week, J&J said Caplyta met its key goals in a second late-stage study in bipolar mania.

Caplyta was a key asset in J&J’s $14.6 billion acquisition of Intra-Cellular Therapies last year.

Share:on TelegramXFacebook

Subscribe to our newsletter

Once a week — the best stories from our editors, no ads or push notifications. Delivered Sunday morning.

Comments (0)

Leave a comment

No comments yet. Be the first!